You are here: Home » Current Affairs » Coronavirus » News
Business Standard

IMA questions govt on ayurveda, yoga-based treatment of Covid-19

IMA questioned the scientific basis of the government's recently released protocol based on ayurveda and yoga for the prevention as well as treatment of asymptomatic and mild patients of COVID-19.

Topics
indian medical association | Coronavirus

Press Trust of India  |  New Delhi 

Coronavirus, covid, tests

The on Thursday questioned the scientific basis of the government's recently released protocol based on ayurveda and yoga for the prevention as well as treatment of asymptomatic and mild patients of COVID-19.

Union Health Minister Harsh Vardhan on Tuesday released a protocol for the clinical management of COVID-19, that lists dietary measures, yoga and ayurvedic herbs and formulations such as Ashwagandha and AYUSH-64 for prevention of infection and treatment of mild and asymptomatic cases.

"Whether the proponents of this claim and his Ministry are prepared to subject themselves as volunteers to an independent prospective double-blind control study in prevention and treatment of COVID? How many of his ministerial colleagues have so far made the informed choice of getting treated under these protocols?" the IMA asked.

"What is stopping him from handing over COVID care and control to AYUSH ministry? IMA demands that the Union Health Minister should come clean on the above posers. If not, he is inflicting a fraud on the nation and gullible patients by calling placebos as drugs," it added.

Questioning the scientific basis of these protocols, the IMA has asked the health minister "to give reproducibility of a claim elsewhere in non-conflict situations and double blind control studies".

A double blind study is a randomized clinical trial in which the person does not know if they are receiving the experimental treatment, a standard treatment or a placebo. Placebo is a substance or treatment which is designed to have no therapeutic value.

"Is there satisfactory evidence regarding the claims made from studies done on COVID-19 patients based on the above criteria? If so, whether the evidence is weak or moderate or strong? The evidence should be in public domain and available for scientific scrutiny," it said in a statement.

The IMA asked "whether the severe form of COVID-19 a hyperimmune status or an immune deficiency status?"

The IMA demanded that the Union Health Minister respond to these posers. "If not, he is inflicting a fraud on the nation and gullible patients by calling placebos as drugs," it said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, October 08 2020. 22:32 IST
RECOMMENDED FOR YOU